Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Pneumagen, a UK-based glycobiologic therapy developer spun out of University of St Andrews, received £4m ($4.9m) yesterday in a round led by life sciences investor Thairm Bio and featuring Scottish Investment Bank, part of economic development agency Scottish Enterprise. The funding will help progress Pneumagen’s candidate – a carbohydrate-binding compound derived from bacterial glycosidases – into clinical trials for Covid-19, although it may also treat respiratory syncytial virus and the flu. Pneumagen claims its approach could provide greater protection against…
